INTRODUCTION
Diabetes is one of the most dreadful diseases affecting mankind of all ages. According to a recent World Health Organization (WHO) report, India, with 32 million diabetic individuals in 2000, currently has the highest incidence of diabetes worldwide; these numbers are predicted to increase to 80 million by the year 2030. 1 Diabetic nephropathy (DN), which carries a heavy clinical and economic burden, is present in up to 40% of patients with type 2 diabetes mellitus. 2 Diabetic nephropathy, which is a progressive kidney disease caused by damage of capillaries in the glomeruli of kidney and characterized by nephrotic syndrome and diffuse scarring of glomeruli, is a prime reason for dialysis and renal replacement therapy in many developed countries. 3, 5 Hyperglycemia and increased blood pressure levels are the main risk factors for the development of diabetic nephropathy which increases the risk of death due to cardiovascular causes. 4 Empagliflozin is one of the sodium glucose cotransporter 2 inhibitors and has shown a magnificent effect on lowering blood glucose level by excretion of glucose in urine and helps in decreasing blood pressure. 6, 7 We have reviewed the literature on empagliflozin bringing to focus the mechanism of action, efficacy, safety and pharmacokinetics of this molecule.
Mechanism of action
Kidney mainly contributes to maintenance of blood glucose levels by reabsorption of glucose from glomerular filtrate to blood. All filtered glucose is reabsorbed into the blood by sodium -glucose cotransporters (SGLTs) along with facilitative glucose transporters (GLUTs) in the proximal tubule of nephron. As the plasma concentration of glucose exceeds 180 -200 mg/dl these transporters cannot reabsorb glucose, glucose starts appearing in urine. This reabsorbed glucose in diabetes contributes to increased plasma sugar levels.
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Keywords
By decreasing blood glucose levels and blood pressure, the risks of developing diabetic nephropathy have been decreased resulting in prevention of diabetic nephropathy. It decreases the diabetes-related glomerular hypertrophy, markers of renal inflammation, as well as mesangial matrix expansion and thus ameliorates the early signs of diabetic nephropathy. It has been reported to decrease the onset of renal disease and prolong the progression of severity of renal disease.
Efficacy
The efficacy of Empagliflozin was tested in four randomized placebo controlled clinical trials in diabetic individuals. (Table 1 ) the first three studies were conducted for 24 weeks whereas the last study for 12 weeks. All the above studies affirmed the significant decrease HbA1C levels by using empagliflozin when compared to placebo. The adverse effects reported in placebo group were more or less similar to empagliflozin groups. In the study of Han Ulrich et al reported significant decrease in mean daily glucose, weight and systolic pressure. 11 E. Ferrannini reported the decrease in body weight in empagliflozin group when compared to placebo groups. 14 All the above studies had shown the higher incidence of urinary tract infections and genital tract infections in empagliflozin group than that in Placebo group. One of the above studies had declared the occurrence of frequent hypoglycemic episodes in some individuals in empagliflozin study group due to excretion of glucose in urine frequently. All the above studies had positive insight towards usage of empagliflozin as add on therapy or as monotherapy for treating type II diabetes. The mechanism of action of empagliflozin also suggests that it has the potential to be used in combination with other oral antidiabetic agents as well as insulin to exert additive or synergic effects on lowering glucose levels in type 2 diabetes.
Safety
The drug empagliflozin had no devastating side effects reported in the studies except minor side effects of urinary and genital tract infections. Headache was also reported as a frequent side effect. These neither decrease the efficacy of drug nor create miserable conditions. These can be treated symptomatically. Sometimes hypoglycemic episodes are also being reported. As the empagliflozin efficacy is based on Glomerular filtration rate and depends on the kidney function, it is ideal to monitor the renal function frequently.
Pharmacokinetics
Empagliflozin has an excellent oral bioavailability. It has no interaction with food. Median time to reach maximum plasma concentration ranged from 1. [16] [17] [18] [19] It is also administered with cardiovascular/ antihypertensive compounds (diuretics, verapamil, ramipril and digoxin) and cholesterol lowering agent (simvastatin) in cases of diabetes with hypertension and diabetes with hyperlipidemia. 21, 22 It can be administered with an anticoagulant (warfarin) and an oral contraceptive (ethinylestradiol/ levonorgestrel). 20, 23 There is no effect of empagliflozin on the pharmacokinetics of the above drug and vice versa.
Current status and future directions
Currently empagliflozin is in use as a hypoglycemic agent for many patients suffering from diabetes mellitus. but there is a need to clear the efficacy of this drug in chronic renal failure as glomerular filtration rates decrease in it.
CONCLUSION
Empagliflozin, an SGLT2 inhibitor decreases blood glucose level thus reducing HbA1c. It also reduces arterial stiffness, vascular resistance and blood pressure. Excretion of glucose results in decrease in calories and weight loss. It has good safety profile with mild headache, urinary and genital tract infection. It has excellent oral bioavailability, longer t 1/2 allowing once daily administration with little or no drug-drug interactions. Nevertheless it is a wonder drug in preventing the complications of diabetes mellitus mainly diabetic nephropathy and cardiovascular side effects.
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